DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Short Interest Up 28.4% in May

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Get Free Report) was the target of a significant increase in short interest during the month of May. As of May 31st, there was short interest totalling 1,100,000 shares, an increase of 28.4% from the May 15th total of 856,900 shares. Based on an average daily trading volume, of 99,000 shares, the short-interest ratio is currently 11.1 days. Approximately 2.8% of the company's shares are short sold.

DiaMedica Therapeutics Price Performance

NASDAQ:DMAC traded up $0.06 during trading hours on Tuesday, reaching $3.57. 122,698 shares of the company were exchanged, compared to its average volume of 86,300. The firm has a market cap of $153.08 million, a price-to-earnings ratio of -5.58 and a beta of 1.23. The stock has a 50 day simple moving average of $3.95 and a 200 day simple moving average of $4.93. DiaMedica Therapeutics has a 52-week low of $2.14 and a 52-week high of $6.82.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.18) EPS for the quarter, hitting analysts' consensus estimates of ($0.18). During the same period in the previous year, the company earned ($0.14) earnings per share. On average, analysts predict that DiaMedica Therapeutics will post -0.59 EPS for the current fiscal year.

Institutional Investors Weigh In On DiaMedica Therapeutics

A number of large investors have recently modified their holdings of DMAC. Paragon Associates & Paragon Associates II Joint Venture lifted its position in shares of DiaMedica Therapeutics by 6.7% during the fourth quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 514,784 shares of the company's stock worth $2,795,000 after purchasing an additional 32,170 shares in the last quarter. Susquehanna International Group LLP increased its stake in DiaMedica Therapeutics by 269.5% during the 4th quarter. Susquehanna International Group LLP now owns 374,845 shares of the company's stock worth $2,035,000 after buying an additional 273,395 shares during the period. Northern Trust Corp lifted its holdings in DiaMedica Therapeutics by 49.8% in the 4th quarter. Northern Trust Corp now owns 180,192 shares of the company's stock worth $978,000 after buying an additional 59,902 shares in the last quarter. Royal Bank of Canada lifted its holdings in DiaMedica Therapeutics by 46,879.1% in the 1st quarter. Royal Bank of Canada now owns 155,031 shares of the company's stock worth $588,000 after buying an additional 154,701 shares in the last quarter. Finally, LPL Financial LLC boosted its position in DiaMedica Therapeutics by 8.2% in the 4th quarter. LPL Financial LLC now owns 152,000 shares of the company's stock valued at $825,000 after buying an additional 11,500 shares during the last quarter. Institutional investors and hedge funds own 10.12% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a "buy" rating and issued a $10.00 price target on shares of DiaMedica Therapeutics in a report on Thursday, May 29th.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.